de Boer Daniel Anton 4

What Happened

• Daniel de Boer, CEO of ProQR Therapeutics N.V. (PRQR), reported a purchase of 150,000 common shares on 2026-07-09 at $1.74 per share, for a total transaction value of $261,000. The filing lists the transaction code "P" (purchase), which can indicate an open-market or private purchase.

Key Details

• Transaction date: 2026-07-09
• Price per share: $1.74
• Shares acquired: 150,000
• Total value: $261,000
• Transaction code: P (purchase — open market or private purchase per filing)
• Form 4 filed: 2026-07-13 (filed within the SEC's 2-business-day window for Form 4s)
• Shares owned after transaction: Not specified in the information provided
• No 10b5-1 plan, tax withholding, or other footnotes were supplied in the details you provided

Context

• This was a straight purchase by the CEO. Purchases by insiders are often considered more informative than routine sales because they involve the insider committing personal capital, but they do not prove future performance. Check subsequent filings or patterns of insider activity for a fuller picture.